Assessment of the safety and efficacy of medicinal product PPR-001 based on regulatory polypeptides of the testes


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective: Evaluation of the effectiveness and safety of the drug PPR-001 (lyophilizate) in comparison with placebo in men with impaired spermatogenesis. Materials and Methods: This study was a randomized, double-blind, placebo-controlled, prospective, multicenter, parallel-group research. Results: It was found that the drug has clinical efficacy and a positive effect on the concentration of spermatozoa in the ejaculate, the percentage of progressively mobile forms and the number of morphologically normal forms of spermatozoa was increased in the group of PPR-001. The primary end point was defined as a proportion of patients who had a therapeutic response (TO) at Visit 3. TO meant at least 20% increase in the concentration and/or progressive motility of spermatozoa compared to the baseline level. The hypothesis of Superiority of PPR-001 over placebo based on primary end point was confirmed (the limit of Superiority was more than 27%). In total, AEs were identified in 65 patients out of 100 (34 patients in the PPR-001 group and 31 patients in the placebo group). When assessing the number of patients who had AEs, there were no statistically significant differences between the groups. All identified AEs were of mild severity; during the study. No negative dynamics was found according to the results of the assessment of vital functions, biochemical and clinical blood tests, clinical urinalysis, ECG indicators. Conclusion: The study demonstrated the superiority of PPR-001 over placebo in terms of increasing concentration and motility of spermatozoa in the ejaculate. A significant increase in the number of morphologically normal forms of spermatozoa in the PPR-001 group was also revealed.

全文:

受限制的访问

作者简介

D. Pushkar

FSBEI of Higher Education “Moscow State University of Medicine and Dentistry named after A.I. Evdokimov” of the Ministry of Health of the Russian Federation

academician of RAS, Ph.D., MD, professor, Head of the Department of Urology of A.I. Evdokimov Moscow State University of Medicine and Dentistry Moscow, Russian

Y. Kupriyanov

FSBEI of Higher Education “Moscow State University of Medicine and Dentistry named after A.I. Evdokimov” of the Ministry of Health of the Russian Federation

urologist, Ph.D., Deputy Chief Urologist of Moscow Health Department, associate professor at the Department of Urology of Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow City Hospital named after S.I. Spasokukotsky Moscow, Russian

A. Bernikov

FSBEI of Higher Education “Moscow State University of Medicine and Dentistry named after A.I. Evdokimov” of the Ministry of Health of the Russian Federation

Ph.D., urologist Moscow, Russian

S. Gamidov

FSBI «National Medical Research Center of Obstetrics, Gynecology and Perinatology named after ac. V.I. Kulakov» of the Ministry of Health of the Russian Federation

Ph.D., MD, professor, Chief of the Department of Andrology and Urology Moscow, Russian

A. Teteneva

OGBUZ "Medical and sanitary unit No. 2”

Deputy Chief on Medical Care of OGBUZ "Medical and sanitary unit No. 2" Tomsk, Russian

L. Spivak

LLC ”Family polyclinic No. 4”

Ph.D., MD, urologist, associate professor at the Institute of Urology and Human Reproductive Health, Chief of the Department of Clinical Trials of the Drugs and Diagnostic Tests Moscow region, Korolev, Russian

I. Shormanov

FSBEI of Higher Education "Yaroslavl State University of Medicine" of the Ministry of Health of the Russian Federation

Ph.D., MD, professor, Head of the Department of the Urology and Nephrology Yaroslavl, Russian

A. Novikov

LLC "New clinic" ABIA"

Ph.D., MD, professor at the department of urology of FGBOU VO North-Western State Medical University named after I.I. Mechnikov St. Petersburg, Russian

S. Al-Shukri

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation

Ph.D., MD, professor, Head of the Department of Urology St. Petersburg, Russian

E. Bogdan

LLC "Aurora Medi"

urologist St. Petersburg, Russian

V. Shchukin

LLC "Research Center Eco-safety"

urologist St. Petersburg, Russian

A. Boriskin

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation

Ph.D., associate professor at the Department of Urology St. Petersburg, Russian

参考

  1. Glybochko, V.P., Ayaev Y.G. Practical Urology. M.: Medforum. 2012.Russian @@Глыбочко П.В., Аляев Ю.Г. Практическая урология. М.: Медфорум, 2012.
  2. Tiktinskij O.L., Mikhajlichenko V.V. Andrology. M.: Media Press. 1999.Russian @@Тиктинский О.Л., Михайличенко В.В. Андрология. М.: Медиа Пресс, 1999.
  3. Babakhanzadeh E., Nazari M, Ghasemifar S., Khodadadian A. Some of the Factors Involved in Male Infertility: A Prospective Review.International Journal of General Medicine. 2020;13:29-41.
  4. Vajnbojer F., Gromoll J., Simony M. The physiology of the male sex glands. Andrology. Andrologija. Muzhskoe zdorov’e i disfunkciya reproduktivnoj sistemy [Men’s health and reproductive system disorders]. Je. Nishlag, G.M. Bere (Ed). Moscow: Medicinskoe informacionnoe agenstvo. 2005;3:29-74).
  5. Zhiborev B.N. Genital diseases in pathogenesis of reproductive health disorders in men. Urology. 2008;3:62-67.
  6. Zubarev A.R., Mitkova M.D., Koryakin M.V. Ultrasound Diagnostics of diseases of the external genital organs in men. Moscow: Vidar. 1996.Russian @@Зубарев А.Р., Митькова М.Д., Корякин М.В. Ультразвуковая диагностика заболеваний наружных половых органов у мужчин. Mосква, Vidar. 1996.
  7. Ignashin N.S. Ultrasonography in the diagnosis and treatment of urologic diseases. Moscow:Vidar. 1997.Russian @@Игнашин Н.С. Ультрасонография в дианостике и лечении урологических заболеваний. М., Vidar. 1997.
  8. Koryakin N.V., Akopyan A.S. Analysis of the causes of male infertility. Problemy reprodukcii. 2000;5:68-74.Russian @@Корякин Н.В., АкопянА.С. Анализ причин мужского бесплодия. Проблемы репродукции. 2000;5:68-74.
  9. Cooper T., Jung, Ch.H. Fiziologija sozrevanija spermatozoidov i oplodotvorenie [Physiology of maturation of spermatozoa and fertilization] Andrology. Andrologija. Muzhskoe zdorov’e i disfunkciya reproduktivnoj sistemy [Men’s health and reproductive system disorders]. Je. Nishlag, G.M. Bere (Ed). Moscow: Medicinskoe informacionnoe agenstvo. 2005;4:75-98).
  10. Amaral A., et al. The combined human sperm proteome: cellular pathways and implications for basic and clinical science. Hum Reprod Update. 2014;20(1):40-62.
  11. Agarwal A., et al. Major protein alterations in spermatozoa from infertile men with unilateral varicocele. Reprod Biol Endocrinol. 2015;13:8.
  12. Agarwal A., et al. Differential proteomic profiling of spermatozoal proteins of infertile men with unilateral or bilateral varicocele. Urology. 2015;85(3):580-588.
  13. Agarwal A., et al. Effect of varicocele on semen characteristics according to the new 2010 World Health Organization criteria: a systematic review and meta-analysis. Asian J Androl. 2016;18(2):163-170.
  14. Camargo M., Intasqui P., Bertolla R.P. Proteomic profile of seminal plasma in adolescents and adults with treated and untreated varicocele. Asian J Androl. 2016;18(2):194-201.
  15. Belardin L.B., et al. Alterations in the proliferative/apoptotic equilibrium in semen of adolescents with varicocele. J Assist Reprod Genet. 2016;33(12):1657-1664.
  16. Samanta L., et al. Proteomic signatures of sperm mitochondria in varicocele: clinical utility as biomarkers of varicocele associated infertility. J Urol. 2018;200(2):414-422.
  17. Hetherington L., et al. Deficiency in outer dense fiber 1 is a marker and potential driver of idiopathic male infertility. Mol Cell Proteomics. 2016;15(12):3685-3693.
  18. Shen S., et al.Comparative proteomic study between human normal motility sperm and idiopathic asthenozoospermia. World J Urol. 2013;31(6):1395- 1401.
  19. Herwig R., et al. Proteomic analysis of seminal plasma from infertile patients with oligoasthenoteratozoospermia due to oxidative stress and comparison with fertile volunteers. Fertil Steril. 2013;100(2):355-366.e2.
  20. Xu W., et al. Proteomic characteristics of spermatozoa in normozoospermic patients with infertility. J Proteome. 2012;75(17):5426-5436.
  21. Azpiazu R., et al. High-throughput sperm differential proteomics suggests that epigenetic alterations contribute to failed assisted reproduction. Hum Reprod. 2014;29(6):1225-1237.
  22. Liu X., et al. iTRAQ-based analysis of sperm proteome from normozoospermic men achieving the rescue-ICSI pregnancy after the IVF failure. Clin Proteomics. 2018;15:27.
  23. McReynolds S., et al. Toward the identification of a subset of unexplained infertility: a sperm proteomic approach. Fertil Steril. 2014;102(3):692-699.
  24. Sharma R., et al. Proteomic analysis of human spermatozoa proteins with oxidative stress. Reprod Biol Endocrinol. 2013; 11:48.
  25. Ayaz A., et al. Impact of precise modulation of reactive oxygen species levels on spermatozoa proteins in infertile men. Clin Proteomics. 2015;12(1):4.
  26. Hamada A., et al. Two-dimensional differential in-gel electrophoresis-based proteomics of male gametes in relation to oxidative stress. Fertil Steril. 2013;99(5):1216-1226.e2.
  27. Agarwal A., et al. Spermatozoa protein profiles in cryobanked semen samples from testicular cancer patients before treatment. Fertil Steril. 2015;104(3): e260.
  28. Dias T.R., et al. New insights on the mechanisms affecting fertility in men with non-seminoma testicular cancer before cancer therapy. World J Mens Health. 2018;36:e50.
  29. Nadel D.M., Turek, P.D. Muzhskoe besplodie [Male infertility].Rukovodstvo po klinicheskoj urologii [Guide to Clinical Urology] (F.M. Hanno, S.B. Malkovich, A.Dzh. Vejn). Moscow: Medicinskoe informacionnoe agentstvo, 2006;21:402-420).
  30. Franca L.R., Hess R.A., Dufour J.M., Hofmann M.C., Griswold M.D. The Sertoli cell: one hundred fifty years of beauty and plasticity. Andrology. 2016;4(2):189-212. doi: 10.1111/andr.12165.
  31. Michael D. Griswold. 50 years of spermatogenesis: Sertoli cells and their interactions with germ cells. Biology of Reproduction. 2018;99(1):87-100 doi: 10.1093/biolre/ioy027.
  32. Khavinson V.K.H., Kuznik B.I., Ryzhak G.A. Peptide bioregulators - a new class of geroprotectors. Uspekhi gerontologii. 2013;26(1):20-37.Russian @@Хавинсон В.Х., Кузник Б.И., Рыжак Г.А. Пептидные биорегуляторы - новый класс геропротекторов. Успехи геронтологии. 2013;26(1):20-37.
  33. Chazov Ye.I. Prospects for the use of peptides in medicine/V kn.: Perspektivy bioorganicheskoy khimii i molekulyarnoy biologii. M.: Nauka, 1986. S. 116-118.Russian @@Чазов Е.И. Перспективы применения пептидов в медицине/В кн.: Перспективы биоорганической химии и молекулярной биологии. М.: Наука, 1986. С. 116-118.
  34. Ashmarin I.P. Regulatory peptides and functionally-continuous functions. Biokhimiya. 1986;51(4):531-545.Russian @@Ашмарин И.П. Регуляторные пептиды, функционально-непрерывная совокупность. Биохимия. 1986;51(4):531-545.
  35. Malinin V.V., Morozov V.G. Mechanisms of peptide regulation of homeostasis. SPb., 2003. 106 c.Russian @@Малинин В.В., Морозов В.Г. Механизмы пептидной регуляции гомеостаза. Клиническая фармакология тимогена. СПб., 2003. 106 c.
  36. Report “Experimental study ofthe toxicity ofthe pharmacological substance Testonorm®. Acute toxicity, phase 1 and 2; mutagenic properties. A study ofthe effect on the spontaneous development oftumors and life expectancy of CBA mice, the reproductive toxicity of a pharmacological substance, allergenic properties of Testonorm and immunotoxic action”. Sankt-Peterburg, 2006.Russian @@Отчет «Экспериментальное исследование токсичности фармакологического вещества Тестонорм®. Острая токсичность, 1-й и 2-й этапы; мутагенные свойства; изучение влияния на развитие спонтанных опухолей и продолжительность жизни мышей линии СВА; изучение репродуктивной токсичности фармакологического вещества; изучение аллергизирующих свойств Тестонорма; изучение иммунотоксического действия». СПб., 2006.
  37. Report “Experimental study ofthe toxicity ofthe pharmacological substance Testonorm®. Chronic toxicity. Sankt-Peterburg, 2007.Russian @@Отчет «Экспериментальное исследование токсичности фармакологического вещества Тестонорм®. Хроническая токсичность. СПб., 2007.
  38. Report "Study of the influence of Testonorm on the functional activity of the testes”. Sankt-Peterburg, 2006.Russian @@Отчет «Изучение влияния Тестонорма на функциональную активность семенников». СПб.,
  39. Report "Study of the influence of Testonorm on organotypic culture of various tissues”. Sankt-Peterburg, 2007.Russian @@Отчет «Изучение влияния Тестонорма на органотипическую культуру различных тканей». СПб., 2007.
  40. Report of the clinical study ANDR-TSN-01, 2018.Russian @@Отчет о клиническом исследовании ANDR-TSN-01, 2018.
  41. Report "Multicenter, blind, placebo-controlled, parallel group randomized clinical phase II trial to evaluate the efficacy and safety of Testonorm®”, 2019 g.Russian @@Отчет «Многоцентровое простое слепое плацебо-контролируемое рандомизированное клиническое исследование II фазы в параллельных группах по изучению эффективности и безопасности препарата «Тестонорм®», 2019.
  42. WHO Laboratory Manual for the Examination and Processing of Human Semen. 5th ed., 2010. Trans. from English N.P. Makarova. Scientific. ed. by L.F. Kurilo. Moscow: Kapital Print, 2012].Russian @@Руководство ВОЗ по исследованию и обработке эякулята человека. 5-е изд., 2010. Пер. с англ. Н.П. Макарова. Науч. ред. Л.Ф. Курило. М.: Капитал Принт, 2012.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2021
##common.cookie##